Avapritinib

Unassigned

New Medicines

Advanced gastrointestinal stromal tumours (GIST)

Information

New molecular entity
Blueprint Medicines Corporation
Blueprint Medicines Corporation

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Tyrosine kinase inhibitor designed to selectively inhibit PDGFRa and KIT, targeting their gene mutations including the PDGFRa D842V and KIT exon 17 mutations.
GISTs are rare. They represent 0.1-3% of all gastrointestinal cancers. However GISTs are the most common primary mesenchymal tumours of the gastrointestinal tract. The estimated incidence of GISTs is around 15 per million of population per annum. There are approximately 900 new cases per year in the UK [1].
Advanced gastrointestinal stromal tumours (GIST)
Oral

Evidence based evaluations